Histogenics logo — Pioneering regenerative solutions for musculoskeletal healin...

Histogenics

Pioneering regenerative solutions for musculoskeletal healing, offering advanced treatments for knee cartilage damage with our innovative platform.

Founded 2000 51-200 employees Post-IPO Equity Total: $226.50M Biotechnology, Health Care

General Information

Company Name Histogenics
Founded Year 2000
Employees 51-200
Industries Biotechnology, Health Care
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Histogenics. To contact Histogenics, visit histogenics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Histogenics compare?

A PDF of Histogenics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Histogenics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Histogenics

Histogenics is a biotechnology company founded in 2000 and is dedicated to advancing regenerative medicine in the musculoskeletal market. The company's slogan, "Pioneering regenerative solutions for musculoskeletal healing, offering advanced treatments for knee cartilage damage with our innovative platform," reflects its core mission. Histogenics' innovative platform integrates expertise in cell processing, scaffolding, tissue engineering, bioadhesives, and growth factors to deliver solutions for musculoskeletal conditions. The company's leading investigational product, NeoCart®, specifically targets orthopedic applications by offering a novel treatment for cartilage damage in the knee. In October 2018, Histogenics secured a $17.00M Post-IPO Equity investment, signifying continued investor interest in the company's regenerative solutions. While the information about the exact location of its headquarters is not provided, the company's focus on regenerative solutions for musculoskeletal healing positions it within the Biotechnology and Health Care industries.

Business keywords: Regenerative Medicine, Tissue Engineering, Musculoskeletal, Orthopedics, Cartilage Regeneration, Cell Processing, Scaffolding, Bioadhesives, Growth Factors, Medical Innovations, Orthopedic Treatments, Innovative Medical Solutions

Funding Rounds & Investors (7)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $17.00M -
05 Oct 2018
Post IPO Equity $30.00M -
13 Oct 2016
Post IPO Equity $70.00M 3
Sofinnova Investments, Split Rock Partners +1
02 Dec 2014
Series A $49.00M 8
The Fintech Fund, Boston Millenia Partners +6
23 Jul 2012
Debt Financing $34.30M -
27 May 2011
Series B $13.10M 2
Boston Millenia Partners, Foundation Medical Partners
04 Sep 2008
Series A $13.10M 2
Stryker, Howmedica
11 Aug 2006

Histogenics Alternatives & Competitors

View All Alternatives
Histogenics vs

From replacement to regeneration

11 employees
Biotechnology, Health Care
Histogenics vs

We aim to reduce patient suffering from meniscus and articular cartilage injury or degeneration by c...

Venture round
9 employees
Biotechnology, Health Care
Histogenics vs

Innovation ★ Tissue Engineering ★ Cell Therapy ★ Impact

47 employees
Biotechnology, Health Care

FAQ About Histogenics

Pioneering regenerative solutions for musculoskeletal healing, offering advanced treatments for knee cartilage damage with our innovative platform.
Histogenics was founded in 2000.
Histogenics operates in Biotechnology and Health Care. Its work centres on Regenerative Medicine, Tissue Engineering, Musculoskeletal and Orthopedics.
Histogenics has approximately 51-200 employees.
Histogenics has completed 7 funding rounds, raising a total of $226.50M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Histogenics include osteobionix, ORTEQ Sports Medicine, Bonus Biogroup, PUR Biologics, Cartilage Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Histogenics and osteobionix are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Histogenics, https://bouncewatch.com/company/histogenics, updated 20 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes